The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Moiseev A.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Guriyanova A.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Suntsova M.V.

World-Class Research Center "Digital biodesign and personalized healthcare" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Buzdin A.A.

Moscow Institute of Physics and Technology;
World-Class Research Center "Digital biodesign and personalized healthcare" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Sorokin M.I.

Moscow Institute of Physics and Technology;
World-Class Research Center "Digital biodesign and personalized healthcare" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

A case of whole-exome and transcriptome sequencing of tumor for personalized experimental treatment for metastatic mesothelioma

Authors:

Moiseev A.A., Guriyanova A.A., Suntsova M.V., Buzdin A.A., Sorokin M.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(2): 62‑67

DOI: 10.17116/onkolog20221102162

Read: 1459 times

Download PDF (RU)
Contact the author
Table of contents

A CASE OF WHOLE-EXOME AND TRANSCRIPTOME SEQUENCING OF TUMOR FOR PERSONALIZED EXPERIMENTAL TREATMENT FOR METASTATIC MESOTHELIOMA
A CASE OF WHOLE-EXOME AND TRANSCRIPTOME SEQUENCING OF TUMOR FOR PERSONALIZED EXPERIMENTAL TREATMENT FOR METASTATIC MESOTHELIOMA

To cite this article:

Moiseev AA, Guriyanova AA, Suntsova MV, Buzdin AA, Sorokin MI. A case of whole-exome and transcriptome sequencing of tumor for personalized experimental treatment for metastatic mesothelioma. P.A. Herzen Journal of Oncology. 2022;11(2):62‑67. (In Russ.)
https://doi.org/10.17116/onkolog20221102162

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
Abstract:

A case report of a female patient, 48 y.o., with metastatic mesothelioma and failure after surgery and standard treatment. Profiling tumor transcriptome and exome using genetic test Oncobox allowed to personalize 4th line of therapy and to prescribe experimental treatment scheme including pembrolizumab, bevacizumab and vinorelbine. A partial response (according to RECIST) and improvement in quality of life of the patient were achieved due to the therapy.

Keywords:

metastatic mesothelioma
pembrolizumab
bevacizumab
vinorelbine
personalized molecular diagnostics
RNA sequencing
whole-exome sequencing
transcriptome analysis
Oncobox
experimental therapy

Authors:

Moiseev A.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Guriyanova A.A.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Suntsova M.V.

World-Class Research Center "Digital biodesign and personalized healthcare" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Buzdin A.A.

Moscow Institute of Physics and Technology;
World-Class Research Center "Digital biodesign and personalized healthcare" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Sorokin M.I.

Moscow Institute of Physics and Technology;
World-Class Research Center "Digital biodesign and personalized healthcare" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Received:

23.11.2021

Accepted:

13.12.2021

Close metadata

References:

  1. Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: A review. Ann Transl Med. 2017;5(11):236.  https://doi.org/10.21037/ATM.2017.03.96
  2. Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: A review. Transl Lung Cancer Res. 2018;7(5):537-542.  https://doi.org/10.21037/tlcr.2018.10.04
  3. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JActivity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis. Lung Cancer. 2002;38(2):111-121.  https://doi.org/10.1016/S0169-5002(02)00180-0
  4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-2644. https://doi.org/10.1200/JCO.2003.11.136
  5. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405-1414. https://doi.org/10.1016/S0140-6736(15)01238-6
  6. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling T, et al. NCCN Guidelines: Insights malignant pleural mesothelioma, version 3.2016. JNCCN J Natl Compr Cancer Netw. 2016;14(7):825-836.  https://doi.org/10.6004/jnccn.2016.0087
  7. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386.  https://doi.org/10.1016/S0140-6736(20)32714-8
  8. All-Russian National Union «Association of Oncologists of Russia», Public organization «Russian Society of Clinical Oncology» Clinical guidelines, Mesothelioma of the pleura, peritoneum and other localizations. (In Russ.). https://oncology-association.ru/wp-content/uploads/2020/09/mezotelioma_plevry.pdf
  9. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008; 26(10):1698-1704. https://doi.org/10.1200/JCO.2006.09.9887
  10. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75(3):360-367.  https://doi.org/10.1016/j.lungcan.2011.08.011
  11. Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014;84(3):271-274.  https://doi.org/10.1016/j.lungcan.2014.03.006
  12. Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E. Analysis of expression of PTEN/PI3K pathway and programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer. 2016;96:1-6.  https://doi.org/10.1016/j.lungcan.2016.03.001
  13. Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239-253.  https://doi.org/10.1016/S1470-2045(18)30765-4
  14. Network NCC. Malignant Pleural Mesothelioma (Version 2.2021). Accessed 06.11.21.  https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf
  15. Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL. A phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010;10):1655-1661. https://doi.org/10.1097/JTO.0b013e3181ec18db
  16. Stahel RA, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz I, Peters S. Searching for targets for the systemic therapy of mesothelioma. Ann Oncol. 2015;26(8):1649-1660. https://doi.org/10.1093/annonc/mdv101
  17. Tkachev V, Sorokin M, Garazha A, Borisov N, Buzdin A. Oncobox method for scoring efficiencies of anticancer drugs based on gene expression data. Methods Mol Biol. 2020;2063:235-255.  https://doi.org/10.1007/978-1-0716-0138-9_17
  18. Buzdin A, Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E, Sekacheva M, Kim E, Gaifullin N, Giese A, Seryakov A, Rumiantsev P, Moshkovskii S, Moiseev A. RNA sequencing for research and diagnostics in clinical oncology. Semin Cancer Biol. 2020;60:311-323.  https://doi.org/10.1016/J.SEMCANCER.2019.07.010
  19. Sorokin M, Borisov N, Kuzmin D, Gudkov A, Zolotovskaia M, Garazha A, Buzdin A. Algorithmic annotation of functional roles for components of 3,044 human molecular pathways. Front Genet. 2021;12:617059. https://doi.org/10.3389/FGENE.2021.617059
  20. Poddubskaya E,, Bondarenko A, Boroda A, Zotova E, Glusker A, Sletina S, Makovskaia L, Kopylov P, Sekacheva M, Moisseev A, Baranova M. Transcriptomics-guided personalized prescription of targeted therapeutics for metastatic ALK-positive lung cancer case following recurrence on ALK inhibitors. Front Oncol. 2019;9:1026. https://doi.org/10.3389/FONC.2019.01026
  21. Poddubskaya EV, Baranova MP, Allina DO, Sekacheva MI, Makovskaia LA, Kamashev DE, Suntsova MV, Barbara VS, Kochergina-Nikitskaya IN, Aleshin AA. Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. Cold Spring Harb Mol case Stud. 2019;5(2):a003434. https://doi.org/10.1101/MCS.A003434
  22. Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, Allina D, Suntsova M, Tkachev V, Garazha A, Sekacheva M, Buzdin A. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol case Stud. 2020;6(2):a004945. https://doi.org/10.1101/MCS.A004945
  23. Moisseev A, Albert E, Lubarsky D, Schroeder D, Clark J. Transcriptomic and genomic testing to guide individualized treatment in chemoresistant gastric cancer case. Biomedicines. 2020;8(3):67.  https://doi.org/10.3390/BIOMEDICINES8030067
  24. Poddubskaya EV, Baranova MP, Allina DO, Smirnov PY, Albert EA, Kirilchev AP, Aleshin AA, Sekacheva MI, Suntsova MV. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol. 2018;7:21.  https://doi.org/10.1186/S40164-018-0113-X
  25. Samii A, Sorokin M, Kar S, Makovskaia L, Garazha A, Hartmann C, Moisseev A, Kim E, Giese A, Buzdin A. Case of multifocal glioblastoma with four fusion transcripts of ALK, FGFR2, NTRK2, and NTRK3 genes stresses the need for tumor tissue multisampling for transcriptomic analysis. Cold Spring Harb Mol Case Stud. 2021;7(4):a0060100. https://doi.org/10.1101/MCS.A006100
  26. Kim EL, Sorokin M, Kantelhardt SR, Kalasauskas D, Sprang B, Fauss J, Ringel F, Garazha A, Albert E, et al. Intratumoral heterogeneity and longitudinal changes in gene expression predict differential drug sensitivity in newly diagnosed and recurrent glioblastoma. Cancers (Basel). 2020;12(2):520.  https://doi.org/10.3390/CANCERS12020520
  27. Seryakov A, Magomedova Z, Suntsova M, Prokofieva A, Rabushko E, Glusker A, Makovskaia L, Zolotovskaia M, Buzdin A, Sorokin M. RNA sequencing for personalized treatment of metastatic leiomyosarcoma: Case report. Front Oncol. 2021;11:666001. https://doi.org/10.3389/FONC.2021.666001
  28. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-775.  https://doi.org/10.1158/1078-0432.CCR-13-2287
  29. Suntsova M, Gaifullin N, Allina D, Reshetun A, Li X, Mendeleeva L, Surin V, Sergeeva A, Spirin P, Prassolov V, Morgan A, Garazha A, Sorokin M, Buzdin A. Atlas of RNA sequencing profiles for normal human tissues. Sci Data. 2019;6(1):36.  https://doi.org/10.1038/S41597-019-0043-4
  30. Buzdin A, Tkachev V, Zolotovskaia M, Garazha A, Moshkovskii S, Borisov N, Gaifullin N, Sorokin M, Suntsova M. Using proteomic and transcriptomic data to assess activation of intracellular molecular pathways. Adv Protein Chem Struct Biol. 2021;127:1-53.  https://doi.org/10.1016/BS.APCSB.2021.02.005
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.